multiple sclerosis and glp 1 Frontiers Understanding GLP-1 receptor agonists and

Treatment with GLP1 Receptor Agonists Reduce Serum CRP Concentrations in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Obesity is a chronic, neurometabolic disease, which has now reached pandemic dimensions with continuing increasing numbers of affected individuals worldwide

J Clin Invest 124: 4473-4488, 2014

The answer is more complexand more interestingthan most people think

( Figure 5 ) Briefly, SGLT2i inhibits the SGLT receptors in the proximal tubule, which inhibits the reabsorption of glucose from primary urine, resulting in glycosuria and a decrease in HbA1c and fasting glucose levels ( Figure 5 Clinical implications Given the significant cardioprotective effect of SGLT2i and GLP-1RAs, the ADA guidelines state that all diabetic patients with confirmed or subclinical cardiovascular disease should be prescribed a GLP-1RA class or SGLT2i class with proven cardiovascular benefit, regardless of the patients HbA1c level or the presence of other glucose-lowering medications ( Strengths and limitations To the best of our knowledge, this is the first meta-analysis to assess the effects of SGLT2i and GLP-1RAs as first-line therapeutic agents in T2DM patients with low cardiovascular disease risk

Available from: Bawa T, Dhingra V, Malhotra N, Wasir JS, Mithal A